Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,081 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, Oh-Hara T, Fujita N, Yanagitani N, Nishio M, Okubo K, Katayama R. Takahashi K, et al. Among authors: seto y. Thorac Cancer. 2020 Mar;11(3):581-587. doi: 10.1111/1759-7714.13299. Epub 2020 Jan 13. Thorac Cancer. 2020. PMID: 31943796 Free PMC article.
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T. Katayama R, et al. Among authors: seto y. Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z. Nat Commun. 2019. PMID: 31399568 Free PMC article.
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.
Yoshizawa T, Uchibori K, Araki M, Matsumoto S, Ma B, Kanada R, Seto Y, Oh-Hara T, Koike S, Ariyasu R, Kitazono S, Ninomiya H, Takeuchi K, Yanagitani N, Takagi S, Kishi K, Fujita N, Okuno Y, Nishio M, Katayama R. Yoshizawa T, et al. Among authors: seto y. NPJ Precis Oncol. 2021 Apr 16;5(1):32. doi: 10.1038/s41698-021-00170-7. NPJ Precis Oncol. 2021. PMID: 33863983 Free PMC article.
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation.
Sagawa R, Sakata S, Gong B, Seto Y, Takemoto A, Takagi S, Ninomiya H, Yanagitani N, Nakao M, Mun M, Uchibori K, Nishio M, Miyazaki Y, Shiraishi Y, Ogawa S, Kataoka K, Fujita N, Takeuchi K, Katayama R. Sagawa R, et al. Among authors: seto y. JCI Insight. 2022 Jan 11;7(1):e153323. doi: 10.1172/jci.insight.153323. JCI Insight. 2022. PMID: 34874919 Free PMC article.
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H. Chen M, et al. Among authors: seto y. Br J Cancer. 2024 Jan;130(1):151-162. doi: 10.1038/s41416-023-02484-8. Epub 2023 Nov 15. Br J Cancer. 2024. PMID: 37968472 Free PMC article.
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.
Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S, Baba S, Takemoto A, Huang T, Seto Y, Saito M, Funauchi Y, Ae K, Takeuchi K, Fujita N, Katayama R. Takagi S, et al. Among authors: seto y. Oncogene. 2024 Dec 11. doi: 10.1038/s41388-024-03251-6. Online ahead of print. Oncogene. 2024. PMID: 39663392
1,081 results